Trial Profile
A randomised controlled trial with rivaroxaban and apixaban in the treatment for venous thromboembolism in cancer patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Mar 2021
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Rivaroxaban (Primary)
- Indications Venous thromboembolism
- Focus Therapeutic Use
- 28 Mar 2021 Status changed from suspended to completed.
- 19 Mar 2020 Status changed from recruiting to suspended.
- 20 Mar 2017 New trial record